Most Read Articles
Pearl Toh, 30 Apr 2021
The PARP inhibitor rucaparib significantly improves progression-free survival (PFS) in patients with recurrent, advanced BRCA-positive ovarian cancer compared with standard-of-care chemotherapy, according to the ARIEL4 study presented at the SGO 2021 Meeting.
Audrey Abella, Yesterday
The addition of the oral, small-molecule tyrosine kinase inhibitor apatinib to pegylated liposomal doxorubicin (PLD) led to a significant improvement in progression-free survival (PFS) among women with platinum-resistant or refractory recurrent ovarian cancer* compared with PLD alone, according to the results of the APPROVE trial presented at SGO 2021.

Chronic hypertension adversely affects pregnancy outcomes

24 Apr 2021

Pregnant women with chronic hypertension are more likely to have unfavourable maternal, foetal, and neonatal outcomes compared with their normotensive counterparts, according to the results of a meta-analysis. Furthermore, exposure to blood-pressure (BP) lowering treatment may contribute to a higher risk of small for gestational age (SGA).

The current systematic review and meta‐analysis pooled data from 94 studies, of which 81 assessed the effect of chronic hypertension while 16 examined that of antihypertensive treatment. Funnel plots and Egger’s test indicated no significant publication bias. The total scores for studies' quality according to Newcastle‐Ottawa grading ranged from 4 to 9, with poorer quality among studies examining the effect of BP lowering.

Chronic hypertension was associated with increased likelihood of pre-eclampsia (adjusted odd ratio [aOR], 5.43, 95 percent confidence interval [CI], 3.85–7.65), caesarean section (aOR, 1.87, 95 percent CI, 1.6–2.16), maternal mortality (aOR, 4.80, 95 percent CI, 3.04–7.58), preterm birth (aOR, 2.23, 95 percent CI, 1.96–2.53), stillbirth (aOR, 2.32, 95 percent CI, 2.22–2.42), and SGA (aOR, 1.96, 95 percent CI, 1.6–2.40). The associations persisted even after controlling for maternal race/ethnicity in subgroup analyses.

Meanwhile, women with chronic hypertension on antihypertensive treatment had higher odds of SGA compared with those who received no treatment (aOR, 1.86, 95 percent CI, 1.38–2.50).

More studies are needed to establish whether the association between BP-lowering therapy and SGA is a direct effect of the treatment or because severe hypertension during pregnancy is a risk factor for SGA and women with severe hypertension are more likely to be treated.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 30 Apr 2021
The PARP inhibitor rucaparib significantly improves progression-free survival (PFS) in patients with recurrent, advanced BRCA-positive ovarian cancer compared with standard-of-care chemotherapy, according to the ARIEL4 study presented at the SGO 2021 Meeting.
Audrey Abella, Yesterday
The addition of the oral, small-molecule tyrosine kinase inhibitor apatinib to pegylated liposomal doxorubicin (PLD) led to a significant improvement in progression-free survival (PFS) among women with platinum-resistant or refractory recurrent ovarian cancer* compared with PLD alone, according to the results of the APPROVE trial presented at SGO 2021.